Log In
Print
BCIQ
Print
Print this Print this
 

STP909

  Manage Alerts
Collapse Summary General Information
Company Sirnaomics Inc.
DescriptionTwo siRNA duplexes against HPV types 16 and 18 formulated with a histidine-lysine co-polymer into nanoparticles
Molecular Target
Mechanism of Action 
Therapeutic ModalityNucleic acid: Linear RNA: siRNA
Latest Stage of DevelopmentPreclinical
Standard IndicationHuman papillomavirus (HPV)
Indication DetailsTreat HPV infection
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today